ACRO Biomedical Co Stock

ACRO Biomedical Co Equity

The The Equity of ACRO Biomedical Co (ACBM) as of Jul 25, 2026 is -387,000.00 USD. In the previous year, The Equity was -295,000.00 USD — a change of 31.19% (lower).

Equity

-387,000.00USD

YoY

31.19%

Last updated:

In 2026, ACRO Biomedical Co's equity was -387,000.00 USD, a 31.19% increase from the -295,000.00 USD equity in the previous year.

Access this data via the Eulerpool API

ACRO Biomedical Co Stock analysis

What does ACRO Biomedical Co do? ACRO Biomedical Co Ltd is a leading company in biomedical technology based in Taipei, Taiwan. The company was established in 2006 and has since successfully established itself in the global market for biomedical products and technologies. The company's vision is to improve people's lives and promote health worldwide through innovative and high-quality products and solutions. Business model: ACRO Biomedical Co Ltd specializes in the development, manufacturing, and marketing of biomedical products and technologies. The company has three main divisions: Regenerative Medicine, Wound Care, and Surgical Technology. Each division focuses on developing products and solutions tailored to the needs of patients and medical professionals. Regenerative Medicine: ACRO Biomedical Co Ltd is a leading provider of regenerative biomedical products. Under this division, the company develops innovative solutions for tissue regeneration, such as bioimplants made from natural tissues and biomaterials to repair or restore damaged tissue. These products are used for the treatment of injuries, chronic diseases, and degenerative conditions. Additionally, ACRO Biomedical Co Ltd has also developed solutions for cosmetic and aesthetic applications. Wound Care: ACRO Biomedical Co Ltd's wound care division specializes in developing products and solutions that help accelerate wound healing, prevent infections, and reduce the risk of complications. The company offers a wide range of products, including antimicrobial and moist wound dressings, which are used for the treatment of acute and chronic wounds such as burns, abrasions, and diabetic foot ulcers. Surgical Technology: ACRO Biomedical Co Ltd's surgical technology division provides healthcare professionals with a wide range of surgical products for various applications, including neurosurgery, plastic surgery, and general surgery. The innovative products offered by ACRO Biomedical Co Ltd for surgical applications include cutting tools, implants, and instruments for minimally invasive procedures. Products: ACRO Biomedical Co Ltd offers a wide range of products for various applications and medical specialties. Some of the company's key products include: - ACL-Bioimplant: A bioimplant for cruciate ligament repair made from human cartilage and biomaterials. - ACRO-CAF: A bone grafting material for bone transplantation. - ACRO-Mixtop: A wound healing agent for the treatment of burns, abrasions, and chronic wounds. - ACRO-OSTEOT: A surgical bone drill for orthopedics and neurosurgery. - ACRO-BioSIS: A tissue adhesive for surgical applications. Summary: ACRO Biomedical Co Ltd is a leading company in biomedical technology that offers innovative solutions for the preservation and restoration of people's health. With its three main divisions: Regenerative Medicine, Wound Care, and Surgical Technology, the company provides a wide range of products and solutions for medical professionals and patients. The company's products are marketed worldwide and are known for their quality, reliability, and effectiveness. ACRO Biomedical Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing ACRO Biomedical Co's Equity

ACRO Biomedical Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding ACRO Biomedical Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating ACRO Biomedical Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

ACRO Biomedical Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in ACRO Biomedical Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about ACRO Biomedical Co stock

The Equity of ACRO Biomedical Co is -387,000.00 USD in 2026.

Access this data via the Eulerpool API

Balance Sheet — ACRO Biomedical Co

All Key Metrics — ACRO Biomedical Co